NCT05018299View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Severe Asthma
Interventions
BIOLOGICAL

FB704A placebo

Placebo

BIOLOGICAL

FB704A

Anti-IL-6 antibody

Trial Locations (7)

Unknown

RECRUITING

NTUH Hsin-Chu Branch, Hsinchu

RECRUITING

China Medical University Hospital, Taichung

ACTIVE_NOT_RECRUITING

Taichung Veterans General Hospital, Taichung

RECRUITING

Ministry of Health and Welfare Shuang-Ho Hospital, Taipei

RECRUITING

Taipei Medical University Hospital, Taipei

RECRUITING

Taipei Municipal Wanfang Hospital, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Oneness Biotech Co., Ltd.

INDUSTRY

NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma | Biotech Hunter | Biotech Hunter